BioCryst Pharmaceuticals, Inc. (BCRX)
8.69
+0.06
(+0.70%)
USD |
NASDAQ |
Mar 03, 16:00
8.69
0.00 (0.00%)
After-Hours: 17:33
BioCryst Pharmaceuticals Research and Development Expense (Annual) : 164.74M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anika Therapeutics, Inc. | 25.77M |
| KalVista Pharmaceuticals, Inc. | 76.72M |
| Lantheus Holdings, Inc. | 177.31M |
| Plus Therapeutics, Inc. | 10.58M |
| BioStem Technologies, Inc. | 1.911M |